Home › Funds › MPM BioImpact LLC › SNDX
MPM BioImpact LLC position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
MPM BioImpact LLC reported holding 1,333,523 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$29.2M, representing 1.78% of its reported portfolio and ranking #22 among its reported holdings. MPM BioImpact LLC has disclosed SNDX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's SNDX position evolved
MPM BioImpact LLC first disclosed a stake in SNDX in Q3 2025 at 1,375,674 shares (US$21.2M). The position peaked in Q1 2026 at 1,340,733 shares, worth US$31.3M. Across 4 filings, MPM BioImpact LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,333,523 shares valued at US$29.2M — a reduction of -7,210 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 1.38M | $21.16M | New |
| Q4 2025 | 1.34M | $28.11M | Reduce |
| Q1 2026 | 1.34M | $31.32M | Hold |
| Q2 2026 | 1.33M | $29.15M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 42 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M sh · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M sh · $33.71M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $28.79M · Q2 2026
- Catalio Capital Management, LP 1.22M sh · $26.58M · Q2 2026
- Prosight Management, LP 1.20M sh · $26.23M · Q2 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.01M sh · $22.18M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held SNDX?
MPM BioImpact LLC has disclosed SNDX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is MPM BioImpact LLC's current position in SNDX?
As of Q2 2026, MPM BioImpact LLC holds 1.33M shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $29.15M, representing 1.78% of its reported portfolio and ranking #22.
Has MPM BioImpact LLC been buying or selling SNDX?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in SNDX. The position peaked in Q1 2026 at 1.34M shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.